Abstract
Fifteen patients with low-grade B-cell tumours were given 3-weekly infusions for 1 year of intravenous immunoglobulin (IVIg) at a dose of 0.4 g/kg. Serial measurements of serum IgG levels were made; analysis of eight samples taken at intervals after the end of the last (17th) infusion showed that the half-life of IgG in such patients was no shorter than in normal individuals. To look at the average rates of catabolism of IgG during the year serum IgG was measured at four time points (pre, post, day 7, and day 21) after the 5th, 8th, 13th, and 17th infusions; these data showed that there were no changes in catabolism. Finally, there was a significant correlation (P<0.005) between the pretreatment serum IgG level and the increase to the mean trough level achieved after the fifth and subsequent infusions (in each individual). These data suggest that the catabolic rate of IgG is normal in patients with low-grade B-cell tumours and that it is not altered by regular IVIg infusions once a steady state is reached. Significant correlation of the increment of serum IgG with the endogenous synthesis level supports the theory that the IgG half-life is proportional to the IgG level at any given time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73:366–368, 1989
Co-operative Group for the Study of Immunoglobulin in CLL: Intravenous immunoglobulin for the presentation of infection in CLL, a randomised, control clinical trial. N Engl J Med 319:902–907, 1988
Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA and Wedgwood RJ: The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112:634–640, 1988
Williams WJ, Bentler E, Enzlev EJ, Rundles RW: Haematology, 2nd ed. New York, McGraw-Hill, 1977, p 938
Waldmann TA, Strobert W: Metabolism of immunoglobulins. Prog Allergy 13:1–110, 1969
Lee ML, Poon N-Y, Kingdom HS: A two-phase linear regression model for biological half-life data. J Lab Clin Med 115:745–748, 1990
Glantz SA, Slinker BK: Primer of Applied Regression Analysis of Variance. New York, McGraw-Hill, 1990, pp 300–302
Barnett V, Lew T: Outliers in Statistical Data. Chichester, UK, John Wiley and Sons, 1978, pp 252–257
Eibl MM, Rosen FS (eds): Excerta Medica International Congress Series 692. Amsterdam, Excerta Medica, 1986, pp 287–292
Ochs HD, Morrell A, Skvrail F, Fischer SH, Wedgwood RJ: Survival of IgG sub-classes following administration of intravenous gamma-globulin in patients with primary immune deficiency diseases.In Clinical Uses of Intravenous Immunoglobulins, A Morrell, UE Nydeggar (eds). London, Academic Press, 1986, pp 77–86
Morell A, Terry WD, Waldmann TA: Metabolic properties of IgG subclasses in man. J Clin Invest 49:673–680, 1970
Wedgwood RJ: Distribution and catabolism of IVIg preparations in immunodeficient patients.In Immunotherapy with Intravenous Immunoglobulins, P Imbach (ed). London, Academic Press, 1991, pp 37–44
Mannhalter JW, Eibl MM: Down regulation of receptors by IV. Int Rev Immunol 5:173–179, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chapel, H.M., Lee, M. Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): Kinetics of immunoglobulin metabolism. J Clin Immunol 12, 17–20 (1992). https://doi.org/10.1007/BF00918268
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00918268